Finally, the PI3K/AKT/NF-κB and JAK/STAT pathways are activated in breast cancer cells, and the activation of these two signaling pathways can produce neoadjuvant chemotherapy drug resistance, which is not conducive to patient treatment [82,83]. The gene discussed is NFKB1; the disease is breast cancer.